SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Traders should monitor Ziihera’s commercial performance and regulatory progress in mGEA, as it directly impacts repayment speed and Royalty Pharma’s return. Zymeworks’ share repurchase activity may provide near-term support, but long-term value hinges on execution and pipeline advancement.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$47.47
T+0 close · Mar 2, 2026 · via day close
Latest settled
+13.46%
T+60 · $53.86
Vs SPY
+4.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $47.47entry
  2. T+1 · 9mo ago +0.02%α +0.94% · $47.48
  3. T+5 · 8mo ago −3.43%α −2.23% · $45.84
  4. T+20 · 8mo ago −2.32%α +5.62% · $46.37
  5. T+60 · 6mo ago +13.46%α +4.13% · $53.86
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royalty Pharma is providing $250 million in non-dilutive, royalty-backed financing to Zymeworks, securing 30% of global tiered royalties from Ziihera® (zanidatamab) sales until repayment is complete. Zymeworks retains 70% of royalties and full rights post-repayment, using the capital for share repurchases, strategic acquisitions, and extending its cash runway beyond 2028.

Key Financial Metrics

Deal Value
$250.0M

Key Facts

  • Royalty Pharma is funding $250 million to Zymeworks via a non-recourse royalty-backed note.
  • Repayment will come from 30% of worldwide tiered royalties on Ziihera sales; Royalty Pharma receives up to 1.65x–1.925x the note amount depending on timing.
  • Zymeworks retains 70% of royalties during repayment and full rights thereafter.
  • Proceeds will support Zymeworks' stock buybacks, potential acquisitions, and cash runway beyond 2028.
  • Zymeworks retains all milestone payments, including up to $1.5 billion in potential future payments from Jazz and BeOne.

Financial Impact

$250 million transaction; Royalty Pharma to receive up to $412.5 million (1.65x) or $481.25 million (1.925x) in cumulative repayments.

revenueroyalty incomecash flow

Risk Factors

  • Repayment depends on Ziihera’s sales performance, which remains early-stage and limited to niche indications.
  • Zymeworks’ ability to generate shareholder value via acquisitions or buybacks is unproven and subject to execution risk.
  • Royalty Pharma’s return is capped, limiting upside despite exposure to a potentially high-growth asset.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247167

Track record

23 reports on RPRX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (13h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026